Calliditas Therapeutics AB Expense By Nature
Calliditas Therapeutics AB reported Expense By Nature of SEK 1.62 billion for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-24.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseByNature · last filed 2024-04-24
| Period end | Expense By Nature 12 month |
|---|---|
| 2023-12-31 | 1.62B SEK 20-F · filed 2024-04-24 |
| 2022-12-31 | 1.23B SEK 20-F · filed 2024-04-24 |
| 2021-12-31 | 754.06M SEK 20-F · filed 2024-04-24 |
| 2020-12-31 | 383.10M SEK 20-F · filed 2023-04-26 |
| 2019-12-31 | 217.23M SEK 20-F · filed 2022-04-27 |
| 2018-12-31 | 132.48M SEK 20-F/A · filed 2022-01-14 |